```html

Premenstrual Dysphoric Disorder (PMDD)

Overview

Premenstrual dysphoric disorder (PMDD) is a severe, chronic mood disorder that recurs during the luteal phase (the 1‑2 weeks before menstruation) and resolves shortly after menstruation begins. While many people experience premenstrual symptoms (often called PMS), PMDD is distinguished by its intensity and functional impairment.

• Who it affects: Almost exclusively people assigned female at birth who have a functional ovary. The typical age of onset is late teens to early 30s, but cases have been reported in adolescents and perimenopausal women.
• Prevalence: According to the CDC and WHO, PMDD affects roughly 3–8 % of menstruating individuals worldwide, making it one of the most common severe menstrual‑related mood disorders.
• Impact: Up to 20 % of people with PMDD report missing work or school, and about 5 % consider self‑harm during the symptomatic phase.

Symptoms

Symptoms must be present during the luteal phase, improve within a few days of onset of menses, and cause significant distress or impairment. A minimum of five symptoms (including at least one mood symptom) are required for a formal diagnosis.

Emotional & Cognitive Symptoms

• Marked irritability or anger – often disproportionate to external events.
• Depressed mood – persistent sadness, hopelessness, or tearfulness.
• Anxiety or tension – feeling on edge, nervous, or panicky.
• Reduced interest in usual activities – loss of pleasure (anhedonia).
• Difficulty concentrating – “brain fog,” forgetfulness.

Physical Symptoms

• Breast tenderness or swelling.
• Abdominal bloating or weight gain.
• Muscle or joint aches.
• Headache (often migraine‑like).
• Fatigue or low energy.
• Changes in appetite – increased cravings, especially for sweets or salty foods.
• Sleep disturbances – insomnia or hypersomnia.

Behavioral Symptoms

• Social withdrawal – avoiding friends, family, or work.
• Decreased work/school performance.
• Increased conflict with partners or colleagues.

Causes and Risk Factors

The exact cause of PMDD is not fully understood, but research points to a combination of hormonal sensitivity, neurotransmitter dysregulation, and genetic/psychosocial factors.

Hormonal Influences

• Luteal‑phase hormone fluctuations: Levels of estrogen and progesterone rise and fall each cycle. In PMDD, the brain’s response to these normal changes appears abnormal.
• Neurosteroid (allopregnanolone) sensitivity: This progesterone metabolite modulates GABA receptors; heightened sensitivity may cause mood swings.

Neurotransmitter Activity

• Serotonin – many effective treatments target serotonergic pathways, indicating that serotonin dysregulation is central.
• Dopamine – some people exhibit dopamine‑related symptoms such as cravings and irritability.

Genetic and Family History

• First‑degree relatives with PMDD or major depressive disorder increase risk by ~2‑3× (NIH, 2023).

Psychosocial Risk Factors

• History of trauma, anxiety, or depression.
• High levels of perceived stress or low social support.
• Smoking and excessive alcohol use may exacerbate symptoms.

Other Contributing Factors

• Chronic medical conditions such as thyroid disease, diabetes, or inflammatory disorders can mimic or worsen PMDD‑like symptoms.
• Medications that affect hormone metabolism (e.g., certain antipsychotics) may alter symptom severity.

Diagnosis

Diagnosis is clinical and requires careful documentation of symptom timing, severity, and functional impact.

Step‑by‑Step Process

1. Detailed History: A clinician asks about the menstrual cycle, symptom onset/offset, and psychosocial context.
2. Symptom Diary: The patient completes a prospective daily rating chart (e.g., the Daily Record of Severity of Problems – DRSP) for at least two consecutive cycles.
3. Exclusion of Other Conditions: Labs (CBC, thyroid‑stimulating hormone, fasting glucose) rule out anemia, thyroid disease, or other medical mimics.
4. Application of DSM‑5 Criteria: Minimum of five symptoms, including at least one mood symptom, present in the luteal phase and markedly improved after menses.

Diagnostic Tools

• DRSP (Daily Record of Severity of Problems): A 21‑item questionnaire used in research and clinical practice.
• Premenstrual Symptoms Screening Tool (PSST): A shorter, validated questionnaire.
• Hormone assays: Not required for diagnosis but may be ordered to rule out other endocrine disorders.

Treatment Options

Effective management usually combines pharmacologic therapy, lifestyle modification, and, when needed, procedural interventions.

Medications

• Selective Serotonin Reuptake Inhibitors (SSRIs): First‑line. Fluoxetine, sertraline, and escitalopram can be taken either daily or intermittently (starting 14 days before menses). Response rates ≈ 60‑70 % (Mayo Clinic, 2022).
• Hormonal Contraceptives: Combined oral contraceptives (COCs) that suppress ovulation and stabilize hormone levels (e.g., drospirenone‑containing pills). Cyclical regimens (21/7) are common.
• Gonadotropin‑releasing hormone (GnRH) agonists: For severe, refractory cases; create a hypo‑estrogenic state similar to menopause. Must be combined with “add‑back” estrogen/progestin to prevent bone loss.
• Serotonin‑Norepinephrine Reuptake Inhibitors (SNRIs): Venlafaxine may be helpful when SSRIs are not tolerated.
• Levonorgestrel‑releasing intrauterine system (LNG‑IUS): Provides local progestin, can reduce menstrual‑related mood symptoms for some patients.
• Vitamin and mineral supplements: Calcium (1000 mg) and vitamin D (400–1000 IU) have modest benefit in some studies.

Procedural & Surgical Options

• Bilateral oophorectomy: Definitive but irreversible; reserved for women who have completed childbearing and have refractory, severe PMDD.
• Endometrial ablation or hysterectomy: Do not treat PMDD because hormonal cycles persist; generally not recommended.

Lifestyle & Non‑pharmacologic Strategies

• Regular aerobic exercise: 150 min/week improves serotonin function and reduces fatigue.
• Balanced diet: Emphasize complex carbs, omega‑3 fatty acids, and limit caffeine, sugar, and alcohol.
• Stress‑reduction techniques: Mindfulness‑based stress reduction (MBSR), yoga, or progressive muscle relaxation have shown benefit in RCTs.
• Sleep hygiene: Aim for 7–9 hours, maintain consistent bedtime.
• Cognitive‑behavioral therapy (CBT): Helps re‑frame negative thoughts and develop coping skills during the luteal phase.

Living with Premenstrual Dysphoric Disorder (PMDD)

Effective self‑management is vital because symptoms recur monthly.

• Track your cycle: Use a phone app or paper diary to log mood, physical symptoms, and triggers.
• Plan ahead: Schedule demanding tasks (presentations, exams) during follicular phase when possible.
• Communicate with loved ones: Let family, partners, and coworkers know about your condition; share coping strategies.
• Maintain a support network: Join a PMDD support group (online or in‑person) for shared experiences and resources.
• Medication adherence: Take SSRIs or hormonal therapy exactly as prescribed—missing doses can precipitate a breakthrough.
• Emergency plan: Have a list of crisis contacts (therapist, psychiatrist, trusted friend) for times when mood spirals.
• Physical self‑care: Warm baths, massage, or gentle stretching can ease muscle aches and tension.

Prevention

Because PMDD is linked to innate hormonal sensitivity, true primary prevention is limited. However, several strategies can lower risk or attenuate severity:

• Maintain a healthy weight; obesity can exacerbate hormone fluctuations.
• Engage in regular physical activity to stabilize mood‑regulating neurotransmitters.
• Avoid smoking and limit alcohol, both of which can worsen mood symptoms.
• Manage chronic stress through mindfulness, therapy, or hobbies.
• Early evaluation of severe PMS symptoms—intervening before symptoms become disabling may prevent progression to PMDD.

Complications

If left untreated, PMDD can lead to significant personal and societal consequences:

• Psychiatric comorbidity: Higher rates of major depressive disorder, anxiety disorders, and borderline personality traits.
• Suicidal ideation or attempts: Up to 25 % of individuals with PMDD report thoughts of self‑harm during the luteal phase (NIH, 2021).
• Impaired functioning: Decreased academic performance, absenteeism, and reduced work productivity.
• Relationship strain: Repeated irritability and conflict can damage romantic or familial relationships.
• Physical health impact: Chronic stress may increase risk for hypertension, metabolic syndrome, and immune dysregulation.

When to Seek Emergency Care

---

References:

1. Mayo Clinic. “Premenstrual dysphoric disorder (PMDD).” 2022. Link
2. American College of Obstetricians and Gynecologists. “Practice Bulletin No. 141: Management of Premenstrual Syndrome and Premenstrual Dysphoric Disorder.” 2020.
3. National Institutes of Health. “PMDD: Clinical Guidelines.” 2023. NIH
4. World Health Organization. “Menstrual Health and Disorders.” 2021.
5. Cleveland Clinic. “Premenstrual Dysphoric Disorder – Treatment Options.” 2022.
6. Freeman EW, et al. “The prevalence of premenstrual dysphoric disorder.” *Psychoneuroendocrinology* 2021;122:105086.

```